Special Issue

Development of Attenuated Vaccine

Message from the Guest Editor

It is a fact from many research results so far that vaccine platforms such as inactivated vaccines and component vaccines cannot induce sufficient protective immunity. Vaccine development has evolved in pathogens, such as: parasites, viruses and bacteria. Here we want to propose the theme aims to contribute to the development of attenuated vaccines by collecting attenuating strategies for a wide range of pathogens. As we are now aware that, the most powerful tools for controlling pathogens is vaccine. Attenuated vaccines are the most powerful tools for inducing protective immunity. Regarding as the development of current genetic engineering with safe and easy way, the development of artificially attenuated vaccines is being realized. In this topic, we call about (1) pathogen-associated molecules targeted by protective immunity, (2) the virulence factor, (3) immune response induced by a genetically manipulated pathogen, and (4) a new vaccine platform. We look forward to call for paper on the subject.

Guest Editor

Dr. Kazutomo Suzue
Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan

Deadline for manuscript submissions

closed (30 June 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/92811

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).